EMA Authorised: Zytiga (abiraterone acetate) — Janssen-Cilag International N.V.

View source ↗

Summary

The EMA authorised Zytiga (abiraterone acetate) from Janssen-Cilag International N.V. for prostate cancer under accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Zytiga (abiraterone acetate)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Janssen-Cilag International N.V.. Decision date: 16/10/2024. Accelerated assessment